[Cancer of the breast: primary prevention of breast cancer by tamoxifen, eligibility criteria, alternatives to English proposals].
During the spring of 1993, UKCCCR prevention trial group proposed to the french medical community to participate into the international breast cancer prevention trial by tamoxifen set up in Great Britain. In January 1994 this proposal was eventually judged unacceptable in France because of lack of reflexion on primary cancer prevention, medico-legal risks, tamoxifen use risks and the eligibility criteria. A randomized trial could be designed and carried out in France to evaluate the place of tamoxifen in breast cancer prevention in the following settings: post menopausal patient with atypical epithelial hyperplasia or lobular in situ carcinoma.
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology / Q000517:prevention & control*; D002278:Carcinoma in Situ / Q000188:drug therapy; D004608:Eligibility Determination; D004992:Ethics, Medical; D005260:Female; D005602:France; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D018579:Patient Selection; D011322:Primary Prevention; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D012307:Risk Factors; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use*; D006113:United Kingdom
D013629:Tamoxifen
Cancer du sein: prévention primaire du cancer du sein par le tamoxifène, tentative de définition de la population cible, alternatives aux propositions anglaises.